Mirae Asset Global Etfs Holdings Ltd. Viridian Therapeutics, Inc.\De Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 31,490 shares of VRDN stock, worth $663,179. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,490Holding current value
$663,179% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
149Shares Held
60.7MCall Options Held
134KPut Options Held
238K-
Black Rock Inc. New York, NY4.77MShares$101 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$82.6 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$81.8 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$70.5 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$69.7 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $840M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...